Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304880 | 0.83 | KCNQ3 (0.68) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12707696 | 0.82 | P4HTM (0.67) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15096729 | 0.80 | GRM4 (0.66) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24033533 | 0.78 | KDM4E (0.44) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14187619 | 0.77 | AURKB (0.61) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30354892 | 0.76 | RAB9A (0.61) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25382636 | 0.76 | RAB9A (0.61) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13210712 | 0.76 | NPC1 (0.64) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5214366 | 0.76 | NPC1 (0.71) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28826499 | 0.76 | KDM4E (0.67) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8093291-B2 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8063057-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2386547-A1 | Multicyclic amino acid derivatives and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-8039086-B2 | Bonding material, process for producing the same, and honeycomb structure made with the same | NGK INSULATORS, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011100285-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TERSERA THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011056916-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7875622-B2 | administering to a patient A therapeutically effective amounts of an endothelin receptor antagonist e.g. ambrisentan, bosentan etc. and (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid to treat pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TPH1, TPH2, PTGIS | KDM4E 2637/4885NPC1 4278/4885RAB9A 3956/4885 |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | TPH2, TPH1, HNMT | KDM4E 2170/4885NPC1 4113/4885RAB9A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.